Real-World data on Faricimab switching in treatment-refractory neovascular Age-Related Macular Degeneration
Ng, Benjamin Kolli, Hema Ajith Kumar, Naduviledeth Azzopardi, Matthew Logeswaran, Abison Buensalido, Julius Mushtaq, Bushra Chavan, Randhir
Ng, Benjamin
Kolli, Hema
Ajith Kumar, Naduviledeth
Azzopardi, Matthew
Logeswaran, Abison
Buensalido, Julius
Mushtaq, Bushra
Chavan, Randhir
Citations
Altmetric:
Affiliation
Sandwell and West Birmingham NHS Trust; University of Oxford; Royal Free Hospital; Moorfields Eye Hospital
Other Contributors
Publication date
2024-01-29
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Faricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict these outcomes; and obtain patient subjective experience on this new injection. This is a retrospective case review with clinical and imaging data from a tertiary referral unit (Birmingham and Midland Eye Centre, UK), involving patients who were switched to faricimab between 1 January and 1 December 2023. In all, 63 eyes (54 patients) with a mean age of 79.2 ± 7.8 and mean of 41.5 ± 22.4 previous anti-VEGF injections were analysed. With a mean of 4.81 ± 1.16 faricimab injections over 6.98 ± 1.75 months, post-treatment visual acuity was logMAR 0.49 ± 0.36 and central macular thickness (CMT) was 320.3 ± 97.9 µm. After first dose, 39.1% achieved complete dryness and 89.1% had anatomical improvement. Presence of subretinal fluid was a predictor of better functional outcomes (p = 0.001, β = -0.182), while initial CMT predicted better anatomical outcomes (p = 0.001, β = 0.688). Compared to their experiences of previous anti-VEGF injections, 89% of patients reported no more discomfort and 87.0% experienced no more floaters, photopsia, or bubbles post-injection. Faricimab switching has anatomical efficacy but limited functional improvement in treatment-refractory AMD. Patient experiences of faricimab compared to previous injections were overall positive.
Citation
Ng B, Kolli H, Ajith Kumar N, Azzopardi M, Logeswaran A, Buensalido J, Mushtaq B, Chavan R, Chong YJ. Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration. Life (Basel). 2024 Jan 29;14(2):193. doi: 10.3390/life14020193
Type
Article